RYVU Therapeutics: KOL Event on RVU120: A First-in-Class CDK8/19i in Phase I Studies for Hematological Malignancies and Solid Tumors
About The Event
The webinar will feature a presentation from Key Opinion Leader (KOL) Dr. Michael Savona, MD (Vanderbilt University School of Medicine) who will discuss the current treatment landscape and unmet medical needs in treating patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).
The Ryvu Therapeutics leadership team will discuss the underlying mechanism of action of RVU120, a highly selective, first-in-class CDK8/19 inhibitor, which targets hematological malignancies and solid tumors characterized by deregulated transcription. Additionally, an update on the Phase I data for RVU120 will be provided.
A live question and answer session will follow the formal presentations.